On October 13, 2026 Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), reported that new Phase 2 data for imneskibart with avelumab in checkpoint inhibitor (CPI)-refractory adenocarcinoma non-small cell lung cancer (NSCLC) will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026. The congress is being held October 23-27, 2026, in Madrid, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:

Title: Imneskibart (AU-007) + low-dose SC IL-2 + avelumab: Phase 2 activity in CPI-refractory advanced adenocarcinoma NSCLC
Abstract: 6280
Presentation Number: 2573P
Session Title: Poster Display session, NSCLC, locally advanced
Date and Time: Monday, October 26, 2026, 12:00 p.m.-12:45 p.m. CET

The abstract will be published online via the ESMO (Free ESMO Whitepaper) website at 12:05 a.m. CEST on October 19, 2026. The poster will be presented in Poster Area – Hall 5 at the IFEMA MADRID. An electronic version will also be available on the ESMO (Free ESMO Whitepaper) Congress 2026 virtual platform.

About Imneskibart
Imneskibart (AU-007) is a human IgG1 monoclonal antibody designed by leveraging artificial intelligence that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, imneskibart redirects IL-2 to reinforce anti-tumor immune effects. This is achieved by preventing IL-2, either exogenous or secreted by effector T cells, from binding to trimeric receptors on regulatory T cells while still allowing IL-2 to bind and expand effector T cells and NK cells. This prevents the negative feedback loop caused by other IL-2-based treatments and biases the immune system toward activation over suppression. Imneskibart also prevents IL-2 from binding to CD25-containing receptors on eosinophils, as well as vasculature and pulmonary endothelium, which may significantly reduce the vascular leak syndrome and pulmonary edema associated with high-dose IL-2 therapy.

To learn more about the imneskibart Phase 1/2 clinical trial program, including study locations in the United States and Australia, please visit ClinicalTrials.gov (identifier: NCT05267626), www.solidtumorstudy.com (U.S.) and www.solidtumourstudy.com (Australia).

(Press release, Aulos Bioscience, OCT 13, 2026, View Source [SID1234673350])

On October 13, 2026 Akiram Therapeutics, a Swedish clinical-stage biotech company specializing in molecular radiotherapy, reported that the first clinical data from the ongoing Phase I trial of its lead drug candidate 177Lu-AKIR001 will be presented at the EANM 2026 Congress in Vienna, October 17–21. Preliminary results show a favorable safety profile within the investigated activity range and sustained tumor retention, supporting continued dose escalation and further clinical evaluation of AKIR001.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract presenting the first clinical results from the ongoing first-in-human trial has been selected as a Top Rated Oral Presentation (TROP) at EANM 2026. The study is evaluating ¹⁷⁷Lu-AKIR001 in patients with irresectable or metastatic CD44v6-positive solid tumors who have no remaining standard treatment options.

At the data cut-off, eight patients had been treated. No dose-limiting toxicities were observed, and treatment-related adverse events were limited to grade 1–2. Four patients received repeat treatment after the first administration.

Quantitative imaging showed sustained tumor retention of ¹⁷⁷Lu-AKIR001, with clearance from blood and normal tissues. Low CD44v6 expression, as determined by immunohistochemistry (IHC), was consistently associated with low absorbed tumor doses. These findings highlight the potential of IHC as a valuable tool for patient stratification and optimized patient selection prior to treatment.

"These first clinical results represent an important milestone for AKIR001. We are encouraged by the safety profile and sustained tumor retention observed so far. It is particularly encouraging that patients have been able to receive repeat treatment, which is an important consideration as development progresses," says Marika Nestor, CEO of Akiram Therapeutics.

A second study involving Akiram’s CD44v6-targeting platform has also been selected as a Top Rated Oral Presentation at EANM 2026. This preclinical study evaluates AKIR001 and a derived scFv antibody format for theranostic applications in bladder cancer, extending the evaluation of Akiram’s approach to a new tumor type and antibody format.

Presentations at EANM 2026

Oral Presentation (Top Rated)
Title: Preliminary results from the ongoing first-in-human clinical trial of anti-CD44v6 agent [¹⁷⁷Lu]Lu-AKIR001
Presentation No.: OP-172
Date & Time: October 18, 4:20 PM
Location: Hall C
Speaker: Joachim Nilsson

Oral Presentation (Top Rated)
Title: Preclinical Evaluation of 177Lu-Labelled CD44v6-Targeted Full-Length and scFv Antibodies for Bladder Cancer Radioimmunotherapy
Presentation No.: OP-599
Date & Time: October 20, 10:05 AM
Location: Hall E2
Speaker: Iris Adriana Maria Lodewijk

AKIR001 is a targeted radiopharmaceutical drug candidate that combines the therapeutic radioisotope lutetium-177 with a proprietary antibody targeting CD44v6, a tumor-associated antigen expressed in several solid tumor types. The approach is designed to deliver radiation selectively to tumor cells while limiting exposure to healthy tissue. AKIR001 is currently being evaluated in a first-in-human Phase I clinical trial (NCT06639191) at Karolinska University Hospital.

EANM in brief
The annual EANM Congress brings together experts, researchers and industry representatives in nuclear medicine to present and discuss scientific and clinical developments in the field. For more information, visit eanm26.eanm.org.

(Press release, Akiram Therapeutics, OCT 13, 2026, View Source [SID1234673349])

On October 12, 2026 ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, reported that it dosed its first patient in the Phase 1 trial in the U.S. with ARR-002 (NCT07755436), a potential first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate (ADC) for ovarian and endometrial cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to have dosed our first patient with ARR-002, our second ADC from our portfolio to enter the clinic," said Stuart Lutzker, MD, Ph.D., President of Research and Development at ArriVent. "Both MUC16 and NaPi2b are highly over-expressed in ovarian and endometrial cancer, and the dual targeting approach of ARR-002 is designed to overcome a key limitation of single-target ADCs in solid tumors where target expression can be heterogenous and can limit effective payload delivery to all tumor cells."

Continues Dr. Lutzker, "The entry of ARR-002 into the clinic for ovarian and endometrial cancer broadens our clinical pipeline beyond lung and gastrointestinal cancers, where we also have active programs."

In August 2026, ArriVent entered into an exclusive licensing agreement with Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize ARR-002 in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan, with all other rights retained by ArriVent.

(Press release, ArriVent Biopharma, OCT 12, 2026, View Source [SID1234673345])

On October 12, 2026 Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, reported that Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, member of Ernexa’s Scientific Advisory Board, and developer of the technology underlying Ernexa’s platform; and Dr. Robert Pierce, Chief Scientific Officer, will participate in the Virtual Investor Closing Bell Series on Thursday, October 15, 2026, at 4:00 PM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of the segment, Mr. Luther, Dr. Rohde and Dr. Pierce will provide a corporate overview and business outlook, highlighting the science underlying Ernexa’s cell therapy platform and the advancement of lead candidate ERNA-101 toward clinical development. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.

A webcast replay will become available two hours following the live presentation and will be accessible for 90 days.

(Press release, Ernexa Therapeutics, OCT 12, 2026, View Source [SID1234673344])

On October 12, 2026 AB Science SA (Euronext – FR0010557264 – AB) reported it will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During this web conference, AB Science will address the following topics:

Status update three months after the implementation of the new governance structure
Review of the September 2026 Sponsor inspection
AB Science’s new outlook and ambitions
Short and medium-term growth drivers
Webinar Information

Conference Date: Wednesday, October 14, 2026. Europe: 6:00 PM – 7:30 PM; US: 12:00 PM – 1:30 PM ET
Webinar registration link: Access the webinar
This web conference will be conducted in French, with presentation materials in English, and will be followed by a Q&A session. The presentation materials in French and English (PDF) will be posted on the AB Science website at the start of the conference.

(Press release, AB Science, OCT 12, 2026, View Source [SID1234673343])